98 related articles for article (PubMed ID: 19757764)
1. Helene Hudson Memorial Lectureship CANO 2008.
Benjaminson P
Can Oncol Nurs J; 2009; 19(2):65-71. PubMed ID: 19757764
[TBL] [Abstract][Full Text] [Related]
2. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
4. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
[TBL] [Abstract][Full Text] [Related]
6. Genetic Testing and Post-Testing Decision Making among BRCA-Positive Mutation Women: A Psychosocial Approach.
Hesse-Biber S; An C
J Genet Couns; 2016 Oct; 25(5):978-92. PubMed ID: 26758254
[TBL] [Abstract][Full Text] [Related]
7. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
Chang-Claude J; Becher H; Caligo M; Eccles D; Evans G; Haites N; Hodgson S; Møller P; Weber BH; Stoppa-Lyonnet D
Dis Markers; 1999 Oct; 15(1-3):53-65. PubMed ID: 10595253
[TBL] [Abstract][Full Text] [Related]
8. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada.
Wolpert N; Warner E; Seminsky MF; Futreal A; Narod SA
Clin Breast Cancer; 2000 Apr; 1(1):57-63; discussion 64-5. PubMed ID: 11899391
[TBL] [Abstract][Full Text] [Related]
10. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.
Mitri ZI; Jackson M; Garby C; Song J; Giordano SH; Hortobágyi GN; Singletary CN; Hashmi SS; Arun BK; Litton JK
Oncologist; 2015 Jun; 20(6):593-7. PubMed ID: 25948675
[TBL] [Abstract][Full Text] [Related]
11. Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
Long J; Evans TG; Bailey D; Lewis MH; Gower-Thomas K; Murray A
Breast J; 2018 Jul; 24(4):580-585. PubMed ID: 29286205
[TBL] [Abstract][Full Text] [Related]
12. Limited family structure and BRCA gene mutation status in single cases of breast cancer.
Weitzel JN; Lagos VI; Cullinane CA; Gambol PJ; Culver JO; Blazer KR; Palomares MR; Lowstuter KJ; MacDonald DJ
JAMA; 2007 Jun; 297(23):2587-95. PubMed ID: 17579227
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
Fackenthal JD; Olopade OI
Nat Rev Cancer; 2007 Dec; 7(12):937-48. PubMed ID: 18034184
[TBL] [Abstract][Full Text] [Related]
14. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.
Derks-Smeets IA; Gietel-Habets JJ; Tibben A; Tjan-Heijnen VC; Meijer-Hoogeveen M; Geraedts JP; van Golde R; Gomez-Garcia E; van den Bogaart E; van Hooijdonk M; de Die-Smulders CE; van Osch LA
Hum Reprod; 2014 May; 29(5):1103-12. PubMed ID: 24603131
[TBL] [Abstract][Full Text] [Related]
15. "It was an Emotional Baby": Previvors' Family Planning Decision-Making Styles about Hereditary Breast and Ovarian Cancer Risk.
Dean M; Rauscher EA
J Genet Couns; 2017 Dec; 26(6):1301-1313. PubMed ID: 28138923
[TBL] [Abstract][Full Text] [Related]
16. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
17. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer.
Gutiérrez-Enríquez S; de la Hoya M; Martínez-Bouzas C; Sanchez de Abajo A; Ramón y Cajal T; Llort G; Blanco I; Beristain E; Díaz-Rubio E; Alonso C; Tejada MI; Caldés T; Diez O
Breast Cancer Res Treat; 2007 May; 103(1):103-7. PubMed ID: 17063271
[TBL] [Abstract][Full Text] [Related]
18. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
Einbeigi Z; Bergman A; Meis-Kindblom JM; Flodin A; Bjursell C; Martinsson T; Kindblom LG; Wahlström J; Wallgren A; Nordling M; Karlsson P
Fam Cancer; 2007; 6(1):35-41. PubMed ID: 16944270
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
